UK School Girls Will Not Benefit From The World’s Leading Four-type Human Papillomavirus (HPV) Vaccine, Gardasil(R) - Sanofi Pasteur MSD Statement
Jun 19th 2008Drug InformationCervical Cancer
The tender decision made by the UK authorities choosing a two-type (16/18) HPV vaccine for their immunisation campaign means that the girls in this campaign will not benefit from the world’s leading four-type (6,11,16,18) HPV vaccine, Gardasil®.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
